Software support for cameras
January 2015—Spot Imaging Solutions has released the Spot 5.2 software, which is designed to provide ongoing operating system support for Spot cameras.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Beckman Coulter Genomics integrates Clarity LIMS
January 2015—Beckman Coulter Genomics has integrated a Genologics Clarity LIMS into its Illumina HiSeq-based next-generation sequencing workflows. RNA sequencing, target capture, whole-genome sequencing, and pre-made library samples are tracked by the laboratory information management system from acquisition through quality control, library prep, and Illumina sequencing. Sample handling is provided for all workflows and chain-of-custody information is preserved.
HTG, Illumina agreement
January 2015—HTG Molecular Diagnostics has entered into an agreement with Illumina in which HTG will have the right to develop certain in vitro diagnostic test kits that use Illumina sequencing technology.
Partnership for TB detection technology
January 2015—FIND, a Geneva-based nonprofit organization, and QuantuMDx Group, a British medical device developer, are joining forces to develop a solution for the combined detection of and drug susceptibility determination for the causative agent for tuberculosis.
Tuberculosis test kit
January 2015—The TB MODS Test Kit, from Hardy Diagnostics, uses the microscopic observation of drug susceptibility (MODS) method to simultaneously detect Mycobacterium tuberculosis and the strain’s resistance to two common tuberculosis antibiotics—isoniazid and rifampicin.
CLSI updated standards and software
January 2015—The Clinical and Laboratory Standards Institute has published two updated standards and released a new version of its StatisPro software. User Verification of Precision and Estimation of Bias; Approved Guideline—Third Edition (EP15-A3) describes the estimation of imprecision and of bias for clinical laboratory quantitative measurement procedures using a protocol that can be completed in five days.
Immunoassays for hydrocodone detection
January 2015—Thermo Fisher Scientific launched its DRI Hydrocodone/Hydromorphone Assay, a homogeneous enzyme immunoassay that specifically detects hydrocodone and major metabolites in human urine at a 300 ng/mL cut-off. The assay uses liquid ready-to-use reagents, calibrators, and controls and can be run in qualitative and semiquantitative modes.
Leica acquisition
January 2015—Leica Biosystems has completed its acquisition of Devicor Medical Products. The Cincinnati-based company has annual revenues of approximately $170 million and more than 550 employees.
Partnerships to develop POC diagnostic tests
January 2015—Chembio Diagnostics announced it has entered into an exclusive agreement with Integrated BioTherapeutics, a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. Under the terms of the agreement, Chembio will combine its patented Dual Path Platform technology with IBT’s proprietary Ebola reagents to develop POC diagnostic tests for Ebola and febrile illness. Chembio will have exclusive rights to any POC product developed through this agreement.
Expanded platforms for hemoglobin A1c test
January 2015—Beckman Coulter Diagnostics has launched its next-generation Hemoglobin A1c assay with improved performance across its chemistry systems. The assay has been standardized for use on all platforms of the company’s AU clinical chemistry systems for off-line sample preparation use and for online sample preparation use on the company’s UniCel DxC systems and is FDA 510(k) cleared for both analyzers.